The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer
Author:
Publisher
Elsevier BV
Subject
Obstetrics and Gynecology,Oncology
Reference93 articles.
1. Overview of anti-angiogenic agents in development for ovarian cancer;Burger;Gynecol Oncol,2011
2. Angiogenesis as a strategic target for ovarian cancer therapy;Spannuth;Nat Clin Pract Oncol,2008
3. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers;Smith;Clin Cancer Res,2010
4. Incorporation of bevacizumab in the primary treatment of ovarian cancer;Burger;N Engl J Med,2011
5. A phase 3 trial of bevacizumab in ovarian cancer;Perren;N Engl J Med,2011
Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. AIM2 Inflammasome in Tumor Cells as a Biomarker for Predicting the Treatment Response to Antiangiogenic Therapy in Epithelial Ovarian Cancer Patients;Journal of Clinical Medicine;2021-09-30
2. Nanomaterials for Antiangiogenic Therapies for Cancer: A Promising Tool for Personalized Medicine;International Journal of Molecular Sciences;2021-02-05
3. Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment;Gynecologic Oncology;2020-10
4. Targeted therapy clinical trials in ovarian cancer: improved outcomes by gene mutation screening;Anti-Cancer Drugs;2020-02
5. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors;Current Pharmaceutical Biotechnology;2019-01-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3